Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non Operating Income (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 14 years of Other Non Operating Income data on record, last reported at -$14.5 million in Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 112.52% year-over-year to -$14.5 million; the TTM value through Sep 2025 reached -$25.9 million, down 302.24%, while the annual FY2024 figure was -$14.4 million, 102.98% down from the prior year.
  • Other Non Operating Income reached -$14.5 million in Q3 2025 per NWBO's latest filing, down from $724000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $58.5 million in Q3 2021 and bottomed at -$93.7 million in Q4 2021.
  • Average Other Non Operating Income over 5 years is -$4.9 million, with a median of -$1.4 million recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: surged 1469.41% in 2021, then plummeted 1793.33% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$93.7 million in 2021, then skyrocketed by 77.68% to -$20.9 million in 2022, then surged by 89.73% to -$2.1 million in 2023, then tumbled by 370.08% to -$10.1 million in 2024, then tumbled by 43.48% to -$14.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$14.5 million in Q3 2025, $724000.0 in Q2 2025, and -$2.0 million in Q1 2025.